Andreas Tiede: PK-Guided Approaches for Recombinant Porcine Factor VIII in Acquired Hemophilia
Andreas Tiede, Professor in the Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation at Hannover Medical School, shared a post on LinkedIn:
“Dosing of Obizur — recombinant porcine factor VIII — can be challenging due to short half-life in bleeding patients with acquired haemophilia. You can read about our experience with PK-guided continuous infusion and bolus dosing in an upcoming JTH article.”
Read the full article here .
Title: Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A
Authors: Justus Heeg, Christiane Dobbelstein, Alfonso Iorio, Heiko Schenk, Benjamin Seeliger, Andreas Tiede
Stay updated on the latest scientific advancements with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH